Anti-VEGFA therapeutic antibody (Pre-made Ranibizumab biosimilar,Fab) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Ranibizumab (trade name Lucentis among others) is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that has been approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion.

Order informatioin

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-470-1mg	1mg	3090
GMP-Bios-ab-470-10mg	10mg	21890
GMP-Bios-ab-470-100mg	100mg	148000
GMP-Bios-ab-470-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Anti-VEGFA therapeutic antibody (Pre-made Ranibizumab biosimilar,Fab)
INN Name	Ranibizumab
Target	VEGFA
Format	Fab
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	Active
100% SI Structure	1cz8:HL:YX
99% SI Structure	None
95-98% SI Structure	1bj1:HL:KJ/6bft:HL:AB
Year Proposed	2004
Year Recommended	2004
Companies	Genentech;Manhattan Eye Ear & Throat Hospital;Novartis Ophthalmics;University of Bonn
Conditions Approved	Choroidal neovascularisation;Degenerative myopia;Diabetic macular oedema;Retinal oedema;Wet age-related macular degeneration;Diabetic retinopathy
Conditions Active	Retinopathy of prematurity;Polypoidal choroidal vasculopathy
Conditions Discontinued	Retinal telangiectasis
Development Tech	na